Stock 61Y MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Marinus Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

61Y

US56854Q2003

Market Closed - Deutsche Boerse AG
Other stock markets
 02:00:39 2024-06-25 EDT 		5-day change 1st Jan Change
1.23 EUR +2.50% Intraday chart for Marinus Pharmaceuticals, Inc. -5.38% -87.38%
06-24 Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index CI
06-17 Sector Update: Health Care Stocks Decline Premarket Monday MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
PR
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index
CI
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
BU
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Top Premarket Decliners
MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
MT
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
BU
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus
CI
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
NE
Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
PR
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit
BU
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. 61Y Stock
  5. News Marinus Pharmaceuticals, Inc.